Recent news on Eplerenone

Too much of a good thing?  -  May 2, 2007
ArabianBusiness.com,Eplerenone (Inspra) does the same thing for heart attack survivors with damage to the left ventricle, the heart's main pumping chamber.

Willingness to pay for a reduction in mortality risk after a ...  -  Apr 21, 2007
HeartZine,Eplerenone is a new medicine that reduces the risk of death after myocardial infarction (MI) but produces additional cost to the health system.

Implant Device Effectively Maintains Heart Function For Transplant ...  -  Apr 1, 2007
Medical News Today (press release),In this study, researchers looked to determine the effect of the aldosterone antagonist eplerenone on patients with left ventricular (LV) dysfunction and

Primary Percutaneous Coronary Intervention  -  Apr 11, 2007
New England Journal of Medicine (subscription),1 , 2 Furthermore, the addition of the selective aldosterone blocker eplerenone to optimal medical therapy has been shown to reduce morbidity and mortality

Health Status Questionnaire Recommended for Heart Failure Management  -  Apr 12, 2007
Medscape (subscription)Dr. Spertus and the other investigators observed 1358 patients participating in the international Eplerenone Neurohormonal Efficacy and Survival Study

Treatment options for heart failure  -  Dec 20, 2006
Casa Grande Valley Newspapers,A newer drug, eplerenone (Inspra), inhibits the action of aldosterone, a hormone that is linked with sodium retention. You'll probably be asked to take home

Treatment options for heart failure  -  Dec 20, 2006
Casa Grande Valley Newspapers,A newer drug, eplerenone (Inspra), inhibits the action of aldosterone, a hormone that is linked with sodium retention. You'll probably be asked to take home

A Novel Mineralocorticoid-Responsive Gene Involved in Aldosterone ...  Jul 27, 2006
...induced by aldosterone. Eplerenone, a specific MR antagonist, inhibited this gene induction by aldosterone in VSMCs. MDM2 protein ... -Am J Pathology (subscription)



New options make heart failure a condition to live with  16 May 2006
Eplerenone (Inspra), first approved by the FDA in 2002 for high blood pressure, is an alternative that seems to cause fewer side effects. ... - DetNews.com





Exelixis Turns X-Ceptor Into Partners: Third Deal Signed  Mar 20, 2006
FDA-approved MR antagonists on the market for hypertension and congestive heart failure due to their vascular protective effects, eplerenone and spironolactone ... - BioWorld Online (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional